血液濃縮器：市場洞察・競合環境・市場予測 (～2030年)

血液濃縮器の市場規模は、2023年の1,163万米ドルから、予測期間中はCAGR 3.24%で推移し、2030年には1,404万米ドルの規模に成長すると予測されています。

血液濃縮器の市場は、心房細動、冠動脈疾患 (CAD) を含む心血管疾患などの慢性疾患の患者の増加、高齢者人口の増加、各国の政府イニシアチブの増加、血液濃縮器の安全性、手頃な価格、使いやすさの改善への注目の高まりなどの要因から、予測期間中の成長が見込まれています。

血液濃縮器：市場力学

World Heart Report (2023) のデータによると、2021年には世界全体で5億人以上が心血管疾患を抱えて生活していると推計されています。また、American Heart Association (2023年) の最近のデータによると、2030年までに世界で1,200万人以上が心房細動に罹患すると推定されています。

British Heart FoundationのGlobal Heart &Circulatory Diseases Factsheet (2024) によると、世界中で約2億人がCADを患っています。血管パッチは動脈修復術、内膜剥離術、動脈瘤再建術などの処置において重要な役割を担っており、治療成績の向上と合併症の最小化をもたらし、現代の心血管系治療において不可欠なものとなっています。これらのことから同市場は拡大しています。

WHOが2021年に発表したデータによると、2015年から2050年の間に60歳以上の高齢者は12%から22%に倍増し、2050年には21億人に達します。さらに2030年には、6人に1人が60歳以上の高齢者となります。高齢者は、心臓、腎臓、および手術や輸液管理を必要とする重篤な疾患の有病率が高くなるため、血液濃縮器市場は高齢化によって牽引される見通しです。

製品タイプ別では、小児用血液濃縮器の部門が2023年に大きな収益シェアを示しました。この製品カテゴリーの急成長は、心臓疾患を患う小児患者の増加によるものです。

小児患者は体が小さく体重も少ないため、乳幼児や新生児のバイパス手術は複雑です。小児用血液濃縮器は、炎症性サイトカインを減少させ、電解質および酸塩基平衡の不均衡を是正し、術後早期の赤血球輸血を制限し、心臓の腫脹を減少させ、小児心臓手術のより良い結果のために外科的切開部の閉鎖を容易にするのに役立ちます。

当レポートでは、世界の血液濃縮器の市場を調査し、市場概要、市場影響因子および市場機会の分析、法規制環境、市場規模の推移・予測、各種区分・地域/主要国別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 血液濃縮器市場レポート：イントロダクション

• 調査範囲
• 市場の分類
• 市場の想定

第2章 血液濃縮器市場：エグゼクティブサマリー

• 市場概要

第3章 競合情勢

第4章 規制分析

• 米国
• 欧州
• 日本
• 中国

第5章 血液濃縮器市場：主要要因分析

• 市場促進要因
  • 心血管疾患の罹患率と負担の増加
  • 世界中で高齢化が進む人口の負担
  • 各国政府の取り組み
• 市場抑制要因と課題
  • 熟練した専門家の不足
  • 手術中の合併症
• 市場機会
  • 意識の高まりによる新興国での成長機会
  • 血液濃縮器の開発ニーズの高まり

第6章 血液濃縮器市場：ポーターのファイブフォース分析

第7章 血液濃縮器市場の評価

• 製品タイプ別
  • 小児用血液濃縮器
  • 成人用血液濃縮器
• エンドユーザー別
  • 病院
  • 外来手術センター
• 地域別
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第8章 血液濃縮器市場：企業・製品プロファイル

• Getinge AB
• LivaNova PLC
• Braile Biomedica
• Terumo Corporation
• MEDICA S.P.A.
• Andocor
• NIPRO CORPORATION
• STERIS
• Chalice Medical Ltd

第9章 KOLの見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項・問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: Hemoconcentrators Market in Global (2021-2030)
• Table 3: Hemoconcentrators Market in Global by Product Type (2021-2030)
• Table 4: Hemoconcentrators Market in Global by End-User (2021-2030)
• Table 5: Hemoconcentrators Market in Global by Geography (2021-2030)
• Table 6: Hemoconcentrators Market in North America (2021-2030)
• Table 7: Hemoconcentrators Market in the United States (2021-2030)
• Table 8: Hemoconcentrators Market in Canada (2021-2030)
• Table 9: Hemoconcentrators Market in Mexico (2021-2030)
• Table 10: Hemoconcentrators Market in Europe (2021-2030)
• Table 11: Hemoconcentrators Market in France (2021-2030)
• Table 12: Hemoconcentrators Market in Germany (2021-2030)
• Table 13: Hemoconcentrators Market in United Kingdom (2021-2030)
• Table 14: Hemoconcentrators Market in Italy (2021-2030)
• Table 15: Hemoconcentrators Market in Spain (2021-2030)
• Table 16: Hemoconcentrators Market in the Rest of Europe (2021-2030)
• Table 17: Hemoconcentrators Market in Asia-Pacific (2021-2030)
• Table 18: Hemoconcentrators Market in China (2021-2030)
• Table 19: Hemoconcentrators Market in Japan (2021-2030)
• Table 20: Hemoconcentrators Market in India (2021-2030)
• Table 21: Hemoconcentrators Market in Australia (2021-2030)
• Table 22: Hemoconcentrators Market in South Korea (2021-2030)
• Table 23: Hemoconcentrators Market in Rest of Asia-Pacific (2021-2030)
• Table 24: Hemoconcentrators Market in the Rest of the World (2021-2030)
• Table 25: Hemoconcentrators Market in the Middle East (2021-2030)
• Table 26: Hemoconcentrators Market in Africa (2021-2030)
• Table 27: Hemoconcentrators Market in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: Hemoconcentrators Market in Global (2021-2030)
• Figure 3: Hemoconcentrators Market in Global by Product Type (2021-2030)
• Figure 4: Hemoconcentrators Market in Global by End-User (2021-2030)
• Figure 5: Hemoconcentrators Market in Global by Geography (2021-2030)
• Figure 6: Hemoconcentrators Market in North America (2021-2030)
• Figure 7: Hemoconcentrators Market in the United States (2021-2030)
• Figure 8: Hemoconcentrators Market in Canada (2021-2030)
• Figure 9: Hemoconcentrators Market in Mexico (2021-2030)
• Figure 10: Hemoconcentrators Market in Europe (2021-2030)
• Figure 11: Hemoconcentrators Market in France (2021-2030)
• Figure 12: Hemoconcentrators Market in Germany (2021-2030)
• Figure 13: Hemoconcentrators Market in United Kingdom (2021-2030)
• Figure 14: Hemoconcentrators Market in Italy (2021-2030)
• Figure 15: Hemoconcentrators Market in Spain (2021-2030)
• Figure 16: Hemoconcentrators Market in the Rest of Europe (2021-2030)
• Figure 17: Hemoconcentrators Market in Asia-Pacific (2021-2030)
• Figure 18: Hemoconcentrators Market in China (2021-2030)
• Figure 19: Hemoconcentrators Market in Japan (2021-2030)
• Figure 20: Hemoconcentrators Market in India (2021-2030)
• Figure 21: Hemoconcentrators Market in Australia (2021-2030)
• Figure 22: Hemoconcentrators Market in South Korea (2021-2030)
• Figure 23: Hemoconcentrators Market in Rest of Asia-Pacific (2021-2030)
• Figure 24: Hemoconcentrators Market in the Rest of the World (2021-2030)
• Figure 25: Hemoconcentrators Market in the Middle East (2021-2030)
• Figure 26: Hemoconcentrators Market in Africa (2021-2030)
• Figure 27: Hemoconcentrators Market in South America (2021-2030)
• Figure 28: Market Drivers
• Figure 29: Market Barriers
• Figure 30: Marker Opportunities
• Figure 31: PORTER'S Five Force Analysis

Hemoconcentrators Market by Product Type (Pediatric Hemoconcentrators and Adult Hemoconcentrators), End-User (Hospitals and Ambulatory Surgical Centres), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a respectable CAGR forecast till 2030 owing to the increase in the prevalence and burden of cardiovascular diseases and escalating burden of the geriatric population globally

The hemoconcentrators market was valued at USD 11.63 million in 2023, growing at a CAGR of 3.24% during the forecast period from 2024 to 2030 to reach USD 14.04 million by 2030. The hemoconcentrators market is slated to witness growth owing to the increasing cases of chronic disorders such as cardiovascular diseases including atrial fibrillation, coronary artery disease (CAD), rising geriatric population, increasing number of government initiatives by countries, growing focus on improving the safety, affordability, and usability of hemoconcentrators among others that are expected to drive the market for hemoconcentrators during the forecast period from 2024 to 2030.

Hemoconcentrators Market Dynamics:

As per data provided by the World Heart Report (2023), in 2021 it was stated that more than half a billion people were living with cardiovascular diseases globally. Further, according to recent data provided by the American Heart Association (2023), it is estimated that by 2030 over 12 million people will have atrial fibrillation globally.

According to British Heart Foundation, Global Heart & Circulatory Diseases Factsheet (2024), it stated that around 200 million people are living with CAD around the world. Vascular patches are vital role in procedures like arterial repairs, endarterectomy, and aneurysm reconstruction, offering improved outcomes and minimizing complications, making them indispensable in contemporary cardiovascular treatments. Hence the market for same is increasing.

The rising prevalence of cardiovascular diseases and associated surgical interventions, such as arterial repairs and aneurysm reconstructions, is driving demand for advanced fluid management solutions. Hemoconcentrators are increasingly essential in maintaining fluid balance during these procedures, improving outcomes and reducing complications, thereby boosting their market growth.

As per data provided by the WHO 2021, between 2015 and 2050, people falling between 60 years and above will be doubled from 12 to 22%, and will eventually reach 2.1 billion by 2050, globally. Moreover, by 2030, 1 in 6 people will age 60 years or above. The aging population is driving the market for hemoconcentrators as older individuals face a higher prevalence of cardiac, renal, and critical conditions requiring surgeries and fluid management, where these devices are essential.

Therefore, the factors stated above collectively will drive the overall hemoconcentrators market during the forecast period from 2024 to 2030.

However, the dearth of skilled professionals, complications during surgery and others may limit their end-user base, thus acting as key constraints limiting the growth of the hemoconcentrators.

Hemoconcentrators Market Segment Analysis:

Hemoconcentrators Market by Product Type (Pediatric Hemoconcentrators and Adult Hemoconcentrators), End-User (Hospitals and Ambulatory Surgical Centres), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product type segment of hemoconcentrators, the pediatric hemoconcentrators category is expected to have a significant revenue share in the year 2023. The rapid growth of this product category is due to the increasing number of pediatric patients with heart diseases is the main reason responsible for the growth of pediatric hemoconcentrators.

According to NHS 2021, one in a hundred babies are born with congenital heart disease in the UK.

As per the Centers for Disease Control and Prevention, 2022, about 1 in 4 babies born with a heart defect have a critical congenital heart defect (CHD).

The increasing importance of pediatric coronary artery bypass surgery (PCABS) for congenital heart disease in infants and children undergoing modern cardiac surgical procedures, because of its life-saving potential in unsuccessful coronary transfer operations is going to increase the demand for pediatric hemoconcentrators.

Due to the small size and low weight of pediatric patients among other factors, performing bypass surgery in infants and neonates is complicated. Pediatric hemoconcentrators help in reducing inflammatory cytokines and correcting electrolyte and acid-base imbalances, limit early postoperative RBCs transfusions, reduces swelling of the heart, and facilitate the closing of surgical incision for better outcome of pediatric cardiac surgery.

For example, CAPIOX(R) HC05 hemoconcentrators by Terumo Corporation is a type of pediatric Hemoconcentrator that efficiently concentrates blood using a polysulfone membrane material at a high ultrafiltration rate.

Therefore, owing to the above-mentioned factors the pediatric hemoconcentrators category is expected to witness substantial growth in the overall hemoconcentrators market during the given forecast period from 2024 to 2030.

North America is expected to dominate the overall hemoconcentrators market:

Among all the regions, North America is expected to dominate the hemoconcentrators market in the year 2023 and is expected to do the same during the forecast period from 2024 to 2030. The increasing prevalence of cardiovascular conditions such as coronary artery disease (CAD), myocardial infarction, and peripheral artery disease (PAD), along with rising comorbidities like hypertension & hyperlipidemia, growing government initiatives in the cardiovascular sector in the US, and presence of key players in the region is expected to drive the continued expansion and innovation in the market for hemoconcentrators during the forecast period from 2024 to 2030.

As per data provided by the National Institute of Health (2023), it stated that 20.5 million people in the US were living with CAD. Furthermore, according to data from the Centers for Disease Control and Prevention (2024), it was stated that 805,000 people in the US have a myocardial infarction every year on average. Furthermore, as per the same source, it was stated that heart disease is an umbrella term that encompasses numerous indications such as acute coronary syndrome, atherosclerosis, and congestive heart failure, among others. Some of the key risk factors associated with heart disease are high blood cholesterol, high blood pressure, and smoking. The source further mentioned that about half of the Americans (47%) have at least one of these three risk factors.

According to data from the Canadian Institute for Health Information (2024), it stated that in 2022, 2.4 million Canadians were affected by heart disease.

Since cardiovascular disorders are rising in the region among middle-aged individuals, the demand for more treatment options is increasing significantly. This trend is fueling investment in innovative technologies and expanding the market for hemoconcentrators.

Also, the presence of key market players in the region is significantly bolstering the market for hemoconcentrators. Major companies have established strong footholds in the region, driving innovation and market growth. The extensive research and development activities, combined with a robust distribution network, enable these players to deliver high-quality, technologically advanced products to a wide end-user base.

Therefore, the interplay of all the aforementioned factors above would provide a conducive growth environment for the North America region in the hemoconcentrators market.

Hemoconcentrators Market key players:

Some of the key market players operating in the hemoconcentrators market include Getinge AB, LivaNova PLC, Braile Biomedica, Terumo Corporation, MEDICA S.P.A., Andocor, NIPRO CORPORATION, STERIS, Chalice Medical Ltd, and others.

Recent Developmental Activities in the Hemoconcentrators Market:

• In June 2021, STERIS completed the acquisition of Cantel Medical which was the parent company of Medivators Inc. and Minntech, leading manufacturers of hemoconcentrators.

Key Takeaways from the Hemoconcentrators Market Report Study

• Market size analysis for current hemoconcentrators market size (2023), and market forecast for 6 years (2024 to 2030)
• Top key product/services developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the hemoconcentrators market
• Various opportunities available for the other competitors in the hemoconcentrators market space
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current hemoconcentrators market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for hemoconcentrators market growth in the coming future?

Target audience who can be benefited from this Hemoconcentrators Market Report Study

• Hemoconcentrators product providers
• Research organizations and consulting companies
• Hemoconcentrators-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in hemoconcentrators
• Various end-users who want to know more about the hemoconcentrators market and the latest developments in the hemoconcentrators market

Frequently Asked Questions for the Hemoconcentrators Market:

1. What are hemoconcentrators?

• The hemoconcentrator is an ultrafiltration device consisting of semipermeable membrane fibers that remove plasma water and solutes. Blood passes through fibers of a microporous membrane, and since the hydrostatic pressure inside the fibers is higher than outside, effluent fluid can pass through the membrane and be drained.

2. What is the market for hemoconcentrators?

• The hemoconcentrators market was valued at USD 11.63 million in 2023, growing at a CAGR of 3.24% during the forecast period from 2024 to 2030 to reach USD 14.04 million by 2030.

3. What are the drivers for the hemoconcentrators market?

• The hemoconcentrators market is slated to witness growth owing to the increasing cases of chronic disorders such as cardiovascular diseases including atrial fibrillation, coronary artery disease (CAD), rising geriatric population, increasing number of government initiatives by countries, growing focus on improving the safety, affordability, and usability of hemoconcentrators among others that are expected to drive the market for hemoconcentrators during the forecast period from 2024 to 2030.

4. Who are the key players operating in the hemoconcentrators market?

• Some of the key market players operating in the hemoconcentrators market include Getinge AB, LivaNova PLC, Braile Biomedica, Terumo Corporation, MEDICA S.P.A., Andocor, NIPRO CORPORATION, STERIS, Chalice Medical Ltd, and others.

5. Which region has the highest share in the hemoconcentrators market?

• Among all the regions, North America is estimated to hold a significant revenue share in the hemoconcentrators market. The increasing prevalence of cardiovascular conditions such as coronary artery disease (CAD), myocardial infarction, and peripheral artery disease (PAD), along with rising comorbidities like hypertension & hyperlipidemia, growing government initiatives in the cardiovascular sector in the US, and presence of key players in the region is expected to drive the continued expansion and innovation in the market for hemoconcentrators during the forecast period from 2024 to 2030.

Table of Contents

1. Hemoconcentrators Market Report Introduction

• 1.1. Scope of the Study
• 1.2. Market Segmentation
• 1.3. Market Assumption

2. Hemoconcentrators Market Executive Summary

• 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1. The United States
• 4.2. Europe
• 4.3. Japan
• 4.4. China

5. Hemoconcentrators Market Key Factors Analysis

• 5.1. Hemoconcentrators Market Drivers
  • 5.1.1. Increase in the prevalence and burden of cardiovascular diseases
  • 5.1.2. The escalating burden of the geriatric population globally
  • 5.1.3. Government initiatives by the countries
• 5.2. Hemoconcentrators Market Restraints and Challenges
  • 5.2.1. The dearth of skilled professionals
  • 5.2.2. Complications during surgery
• 5.3. Hemoconcentrators Market Opportunities
  • 5.3.1. Growth opportunities in emerging countries owing to rising awareness
  • 5.3.2. Rising need to develop hemoconcentrators

6. Hemoconcentrators Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Hemoconcentrators Market Assessment

• 7.1. By Product Type
  • 7.1.1. Pediatric Hemoconcentrators
  • 7.1.2. Adult Hemoconcentrators
• 7.2. By End-User
  • 7.2.1. Hospitals
  • 7.2.2. Ambulatory Surgical Centres
• 7.3. By Geography
  • 7.3.1. North America
    • 7.3.1.1. United States Hemoconcentrators Market Size in USD million (2021-2030)
    • 7.3.1.2. Canada Hemoconcentrators Market Size in USD million (2021-2030)
    • 7.3.1.3. Mexico Hemoconcentrators Market Size in USD million (2021-2030)
  • 7.3.2. Europe
    • 7.3.2.1. France Hemoconcentrators Market Size in USD million (2021-2030)
    • 7.3.2.2. Germany Hemoconcentrators Market Size in USD million (2021-2030)
    • 7.3.2.3. United Kingdom Hemoconcentrators Market Size in USD million (2021-2030)
    • 7.3.2.4. Italy Hemoconcentrators Market Size in USD million (2021-2030)
    • 7.3.2.5. Spain Hemoconcentrators Market Size in USD million (2021-2030)
    • 7.3.2.6. Rest of Europe Hemoconcentrators Market Size in USD million (2021-2030)
  • 7.3.3. Asia-Pacific
    • 7.3.3.1. China Hemoconcentrators Market Size in USD million (2021-2030)
    • 7.3.3.2. Japan Hemoconcentrators Market Size in USD million (2021-2030)
    • 7.3.3.3. India Hemoconcentrators Market Size in USD million (2021-2030)
    • 7.3.3.4. Australia Hemoconcentrators Market Size in USD million (2021-2030)
    • 7.3.3.5. South Korea Hemoconcentrators Market Size in USD million (2021-2030)
    • 7.3.3.6. Rest of Asia-Pacific Hemoconcentrators Market Size in USD million (2021-2030)
  • 7.3.4. Rest of the World (RoW)
    • 7.3.4.1. Middle East Hemoconcentrators Market Size in USD million (2021-2030)
    • 7.3.4.2. Africa Hemoconcentrators Market Size in USD million (2021-2030)
    • 7.3.4.3. South America Hemoconcentrators Market Size in USD million (2021-2030)

8. Hemoconcentrators Market Company and Product Profiles

• 8.1. Getinge AB
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. LivaNova PLC
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. Braile Biomedica
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. Terumo Corporation
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. MEDICA S.P.A.
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Andocor
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. NIPRO CORPORATION
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. STERIS
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Chalice Medical Ltd
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us